Literature DB >> 2059253

Defect in fatty acid oxidation: laboratory and pathologic findings in a patient.

J H Tonsgard1, J K Stephens, W J Rhead, D Penn, A L Horwitz, B S Kirschner, P F Whitington, S Berger, M E Tripp.   

Abstract

The clinical, laboratory, and pathologic findings in a patient with a previously undescribed deficiency in fatty acid oxidation are summarized. The patient had a fatal defect in fatty acid metabolism profoundly affecting heart, skeletal muscle, liver, and kidney. Oxidation of palmitate was 38-51% of controls. Complementation assays demonstrated that the patient's fibroblasts complemented fibroblast lines from all known defects in fatty acid oxidation except long-chain acyl-CoA dehydrogenase deficiency. Urine and serum carnitine profiles also were indicative of a defect in the oxidation of long-chain substrate; however, the palmitoyl-CoA dehydrogenase activity was actually increased. This finding indicates that the patient had a defect that was distinct from, but possibly related to, long-chain acyl-CoA dehydrogenase deficiency. This patient demonstrates the laboratory and pathologic findings in defects in fatty acid oxidation and how they differ from those in Reye syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2059253     DOI: 10.1016/0887-8994(91)90009-a

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients.

Authors:  Julien Baruteau; Philippe Sachs; Pierre Broué; Michèle Brivet; Hendy Abdoul; Christine Vianey-Saban; Hélène Ogier de Baulny
Journal:  J Inherit Metab Dis       Date:  2012-10-03       Impact factor: 4.982

2.  Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients.

Authors:  T Aoyama; M Souri; S Ushikubo; T Kamijo; S Yamaguchi; R I Kelley; W J Rhead; K Uetake; K Tanaka; T Hashimoto
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.